On July 2, 2025, the European Commission announced a bold new initiative to position Europe as the global leader in life sciences by 2030. Presented under the Communication titled “Boosting Biotechnology and Biomanufacturing in the EU”, this strategy aims to unlock the full potential of the life sciences ecosystem in Europe, ensuring the continent remains competitive, innovative, and resilient in the face of global challenges.
With over €10 billion already allocated annually through existing EU programs such as Horizon Europe and EU4Health, the strategy is both ambitious and grounded in tangible financial commitments. The life sciences sector already represents a major component of the EU economy—accounting for over €1.5 trillion in economic activity and supporting 29 million jobs. The new strategy is designed to build on this foundation, addressing gaps in innovation, scale-up capabilities, and regulatory efficiency.
Key Pillars of the Strategy
The Importance of a Robust Life Sciences Strategy
Developing an Effective Life Sciences Strategy
The Commission’s life sciences strategy is structured around three core priorities, each designed to reinforce a different stage of the innovation and commercialization pipeline:
- Strengthening Research and Innovation (R&I)
Europe has long been a hub of academic excellence, but its ability to translate scientific discoveries into scalable innovations has lagged behind global competitors. The strategy seeks to improve this by enhancing coordination across public and private actors, supporting startups and SMEs, and facilitating technology transfer. The goal is to enable faster and more effective commercialization of cutting-edge life science innovations. - Accelerating Market Access
A major bottleneck in life sciences is the regulatory path from discovery to market. The Commission plans to update regulatory frameworks to better accommodate emerging technologies, including genomics, cell and gene therapies, and AI-powered diagnostics. The aim is to create a more predictable and agile regulatory environment without compromising safety or ethical standards. - Ensuring Societal Trust and Adoption
Scientific innovation only achieves its potential when it is understood and trusted by the public. The Commission recognizes the importance of public engagement and transparency in fostering acceptance of new technologies. This includes increased support for stakeholder dialogue, public communication campaigns, and ethical oversight.
A Timely Response to Global Pressures
The global race for leadership in biotechnology and life sciences is intensifying. The United States and China have invested heavily in recent years, and Europe has felt increasing pressure to match their pace and ambition. The COVID-19 pandemic exposed both the strengths and vulnerabilities of Europe’s life sciences infrastructure. While EU companies were instrumental in vaccine development and distribution, there were also clear weaknesses in supply chain resilience and biomanufacturing scale.
This new strategy addresses those shortcomings directly. By creating a more integrated and responsive ecosystem, the EU aims not only to retain talent and investment but also to lead in the next generation of health and bio-based technologies.
Concrete Initiatives on the Horizon
The strategy includes a range of initiatives already in motion or soon to be launched. Among them:
- A call for proposals under Horizon Europe for biotech-based manufacturing and fermentation technologies, with €350 million allocated for 2024–2025.
- New guidance and policy adjustments under the forthcoming EU Biotech and Biomanufacturing Initiative.
- Support for national bioeconomy action plans to foster alignment among Member States.
- Expansion of regulatory sandboxes to test new health innovations in real-world settings under close supervision.
These efforts are expected to improve Europe’s ability to develop and scale new therapeutics, diagnostics, bio-based materials, and green biotech solutions.
Stakeholder Engagement and Implementation
The success of this strategy will rely on effective cooperation across multiple levels: EU institutions, national governments, research organizations, industry, and civil society. The Commission has committed to continued dialogue with stakeholders and will publish regular progress reports to track implementation.
Initial reactions from industry bodies and innovation hubs have been positive. The BioInnovation Institute, among others, has praised the initiative for its focus on enabling early-stage ventures and strengthening the entire life science value chain.
Conclusion: A Defining Moment for Europe’s Life Sciences Sector
The European Commission’s life sciences strategy is both a statement of intent and a blueprint for action. By fostering stronger research collaboration, streamlining regulations, and investing in public trust, Europe is positioning itself to lead the global transition toward more innovative, sustainable, and inclusive health solutions.
For businesses, researchers, and healthcare providers, the message is clear: Europe is open for innovation and ready to shape the future of life sciences. The next five years will be critical in turning this vision into reality.
At 1MED, we are proud to support life science innovators across Europe and beyond—bridging regulatory, clinical, and operational expertise to bring groundbreaking products to market faster and more efficiently.
If you’re developing a novel medical device, combination product, or advanced therapy, and looking for a strategic partner to navigate the evolving EU landscape, get in touch with us today. Let’s shape the future—together, as one, for the patient.
Visit www.1med.net or connect with us directly to start the conversation.